{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T08:01:20Z","timestamp":1789718480352,"version":"4.0.1"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,12,10]],"date-time":"2021-12-10T00:00:00Z","timestamp":1639094400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,12,10]],"date-time":"2021-12-10T00:00:00Z","timestamp":1639094400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100010034","name":"Walailak University","doi-asserted-by":"publisher","award":["The new strategic research (P2P) project"],"award-info":[{"award-number":["The new strategic research (P2P) project"]}],"id":[{"id":"10.13039\/501100010034","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Human African trypanosomiasis (HAT) is endemic in Africa; hence, the possibility of co-infection with malaria among patients with HAT exists. The present study investigated co-infection with malaria among patients with HAT to provide current evidence and characteristics to support further studies. Potentially relevant studies that reported <jats:italic>Plasmodium<\/jats:italic> spp. infection in patients with HAT was searched in PubMed, Web of Science, and Scopus. The risk of bias among the included studies was assessed using the checklist for analytical cross-sectional studies developed by the Joanna Briggs Institute. The pooled prevalence of <jats:italic>Plasmodium<\/jats:italic> spp. infection in patients with HAT was quantitatively synthesized using a random-effects model. Subgroup analyses of study sites and stages of HAT were performed to identify heterogeneity regarding prevalence among the included studies. The heterogeneity of the outcome among the included studies was assessed using Cochran\u2019s Q and <jats:italic>I<\/jats:italic><jats:sup><jats:italic>2<\/jats:italic><\/jats:sup> statistics for consistency. Publication bias was assessed if the number of included studies was 10 or more. For qualitative synthesis, a narrative synthesis of the impact of <jats:italic>Plasmodium<\/jats:italic> spp. infection on the clinical and outcome characteristics of HAT was performed when the included studies provided qualitative data. Among 327 studies identified from three databases, nine studies were included in the systematic review and meta-analysis. The prevalence of <jats:italic>Plasmodium<\/jats:italic> spp. co-infection (692 cases) among patients with HAT (1523 cases) was 50% (95% confidence interval [CI]\u2009=\u200928\u201372%, <jats:italic>I<\/jats:italic><jats:sup>2<\/jats:sup>\u2009=\u200998.1%, seven studies). Subgroup analysis by type of HAT (gambiense or rhodesiense HAT) revealed that among patients with gambiense HAT, the pooled prevalence of <jats:italic>Plasmodium<\/jats:italic> spp. infection was 46% (95% CI\u2009=\u200914\u201378%, <jats:italic>I<\/jats:italic><jats:sup>2<\/jats:sup>\u2009=\u200996.62%, four studies), whereas that among patients with rhodesiense HAT was 44% (95% CI\u2009=\u200940\u201349%, <jats:italic>I<\/jats:italic><jats:sup>2<\/jats:sup>\u2009=\u200998.3%, three studies). Qualitative syntheses demonstrated that <jats:italic>Plasmodium<\/jats:italic> spp. infection in individuals with HAT might influence the risk of encephalopathy syndrome, drug toxicity, and significantly longer corrected QT time. Moreover, longer hospital stays and higher treatment costs were recorded among co-infected individuals. Because of the high prevalence of malaria among patients with HAT, some patients were positive for malaria parasites despite being asymptomatic. Therefore, it is suggested to test every patient with HAT for malaria before HAT treatment. If malaria is present, then antimalarial treatment is recommended before HAT treatment. Antimalarial treatment in patients with HAT might decrease the probability of poor clinical outcomes and case fatality in HAT.<\/jats:p>","DOI":"10.1038\/s41598-021-03295-8","type":"journal-article","created":{"date-parts":[[2021,12,10]],"date-time":"2021-12-10T11:03:37Z","timestamp":1639134217000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Prevalence and outcomes of malaria as co-infection among patients with human African trypanosomiasis: a systematic review and meta-analysis"],"prefix":"10.1038","volume":"11","author":[{"given":"Kwuntida Uthaisar","family":"Kotepui","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederick Ramirez","family":"Masangkay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"De Jesus Milanez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manas","family":"Kotepui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,12,10]]},"reference":[{"issue":"10110","key":"3295_CR1","doi-asserted-by":"publisher","first-page":"2397","DOI":"10.1016\/S0140-6736(17)31510-6","volume":"390","author":"P Buscher","year":"2017","unstructured":"Buscher, P., Cecchi, G., Jamonneau, V. & Priotto, G. Human African trypanosomiasis. Lancet 390(10110), 2397\u20132409 (2017).","journal-title":"Lancet"},{"issue":"5","key":"3295_CR2","doi-asserted-by":"publisher","first-page":"e0008261","DOI":"10.1371\/journal.pntd.0008261","volume":"14","author":"JR Franco","year":"2020","unstructured":"Franco, J. R. et al. Monitoring the elimination of human African trypanosomiasis at continental and country level: Update to 2018. PLoS Negl. Trop. Dis. 14(5), e0008261 (2020).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"3295_CR3","doi-asserted-by":"publisher","first-page":"39","DOI":"10.3389\/fimmu.2019.00039","volume":"10","author":"PGE Kennedy","year":"2019","unstructured":"Kennedy, P. G. E. & Rodgers, J. Clinical and neuropathogenetic aspects of human African trypanosomiasis. Front. Immunol. 10, 39 (2019).","journal-title":"Front. Immunol."},{"issue":"9","key":"3295_CR4","doi-asserted-by":"publisher","first-page":"2334","DOI":"10.1007\/s00415-019-09425-7","volume":"266","author":"PGE Kennedy","year":"2019","unstructured":"Kennedy, P. G. E. Update on human African trypanosomiasis (sleeping sickness). J. Neurol. 266(9), 2334\u20132337 (2019).","journal-title":"J. Neurol."},{"issue":"2","key":"3295_CR5","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/S1474-4422(12)70296-X","volume":"12","author":"PG Kennedy","year":"2013","unstructured":"Kennedy, P. G. Clinical features, diagnosis, and treatment of human African trypanosomiasis (sleeping sickness). Lancet Neurol. 12(2), 186\u2013194 (2013).","journal-title":"Lancet Neurol."},{"issue":"1","key":"3295_CR6","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.actatropica.2005.08.001","volume":"97","author":"J Blum","year":"2006","unstructured":"Blum, J., Schmid, C. & Burri, C. Clinical aspects of 2541 patients with second stage human African trypanosomiasis. Acta Trop. 97(1), 55\u201364 (2006).","journal-title":"Acta Trop."},{"issue":"2","key":"3295_CR7","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1002\/ana.21429","volume":"64","author":"PG Kennedy","year":"2008","unstructured":"Kennedy, P. G. The continuing problem of human African trypanosomiasis (sleeping sickness). Ann. Neurol. 64(2), 116\u2013126 (2008).","journal-title":"Ann. Neurol."},{"issue":"4","key":"3295_CR8","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/j.pcl.2017.03.004","volume":"64","author":"LM Cohee","year":"2017","unstructured":"Cohee, L. M. & Laufer, M. K. Malaria in children. Pediatr. Clin. N. Am. 64(4), 851\u2013866 (2017).","journal-title":"Pediatr. Clin. N. Am."},{"key":"3295_CR9","unstructured":"World Health Organization. World malaria report 2020. 2020. https:\/\/www.who.int\/publications\/i\/item\/9789240015791. Accessed 23 Sep 2021."},{"issue":"1","key":"3295_CR10","doi-asserted-by":"publisher","first-page":"6409","DOI":"10.1038\/s41598-021-85398-w","volume":"11","author":"A Mahittikorn","year":"2021","unstructured":"Mahittikorn, A., Masangkay, F. R., Kotepui, K. U., Milanez, G. J. & Kotepui, M. Comparison of Plasmodium ovale curtisi and Plasmodium ovale wallikeri infections by a meta-analysis approach. Sci. Rep. 11(1), 6409 (2021).","journal-title":"Sci. Rep."},{"issue":"1","key":"3295_CR11","doi-asserted-by":"publisher","first-page":"e2012026","DOI":"10.4084\/mjhid.2012.026","volume":"4","author":"A Bartoloni","year":"2012","unstructured":"Bartoloni, A. & Zammarchi, L. Clinical aspects of uncomplicated and severe malaria. Mediterr. J. Hematol. Infect. Dis. 4(1), e2012026 (2012).","journal-title":"Mediterr. J. Hematol. Infect. Dis."},{"issue":"12","key":"3295_CR12","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1080\/14787210.2019.1693259","volume":"17","author":"J Cheaveau","year":"2019","unstructured":"Cheaveau, J. et al. Asymptomatic malaria in the clinical and public health context. Expert Rev. Anti Infect. Ther. 17(12), 997\u20131010 (2019).","journal-title":"Expert Rev. Anti Infect. Ther."},{"issue":"2","key":"3295_CR13","doi-asserted-by":"publisher","first-page":"814","DOI":"10.3390\/ijerph18020814","volume":"18","author":"K Korzeniewski","year":"2021","unstructured":"Korzeniewski, K., Bylicka-Szczepanowska, E. & Lass, A. Prevalence of asymptomatic malaria infections in seemingly healthy children, the rural Dzanga Sangha region, Central African Republic. Int. J. Environ. Res. Public Health. 18(2), 814 (2021).","journal-title":"Int. J. Environ. Res. Public Health."},{"issue":"1","key":"3295_CR14","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1186\/s12936-020-03344-z","volume":"19","author":"M Kotepui","year":"2020","unstructured":"Kotepui, M., Kotepui, K. U., Milanez, G. D. & Masangkay, F. R. Global prevalence and mortality of severe Plasmodium malariae infection: A systematic review and meta-analysis. Malar. J. 19(1), 274 (2020).","journal-title":"Malar. J."},{"issue":"1","key":"3295_CR15","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1186\/s12879-020-05046-y","volume":"20","author":"M Kotepui","year":"2020","unstructured":"Kotepui, M., Kotepui, K. U., Milanez, G. J. & Masangkay, F. R. Prevalence and risk factors related to poor outcome of patients with severe Plasmodium vivax infection: A systematic review, meta-analysis, and analysis of case reports. BMC Infect. Dis. 20(1), 363 (2020).","journal-title":"BMC Infect. Dis."},{"key":"3295_CR16","unstructured":"World Health Organization. WHO Guidelines for Malaria. (WHO, 2021). https:\/\/www.who.int\/publications-detail-redirect\/guidelines-for-malaria. Accessed 23 Sep 2021."},{"issue":"6","key":"3295_CR17","doi-asserted-by":"publisher","first-page":"e0235014","DOI":"10.1371\/journal.pone.0235014","volume":"15","author":"M Kotepui","year":"2020","unstructured":"Kotepui, M., Kotepui, K. U., Milanez, G. D. & Masangkay, F. R. Severity and mortality of severe Plasmodium ovale infection: A systematic review and meta-analysis. PLoS ONE 15(6), e0235014 (2020).","journal-title":"PLoS ONE"},{"issue":"7","key":"3295_CR18","doi-asserted-by":"publisher","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","volume":"6","author":"D Moher","year":"2009","unstructured":"Moher, D., Liberati, A., Tetzlaff, J. & Altman, D. G. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 6(7), e1000097 (2009).","journal-title":"PLoS Med."},{"key":"3295_CR19","unstructured":"Moola, S. et al. Chapter 7: Systematic Reviews of Etiology and Risk JI. 2020. https:\/\/synthesismanual.jbi.global. Accessed 2 Aug 2021."},{"issue":"3","key":"3295_CR20","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","volume":"7","author":"R DerSimonian","year":"1986","unstructured":"DerSimonian, R. & Laird, N. Meta-analysis in clinical trials. Control Clin. Trials. 7(3), 177\u2013188 (1986).","journal-title":"Control Clin. Trials."},{"key":"3295_CR21","unstructured":"Higgins, J.P.T. (eds). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). https:\/\/www.training.cochrane.org\/handbook (Cochrane, 2021)."},{"issue":"5","key":"3295_CR22","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1046\/j.1365-3156.2001.00710.x","volume":"6","author":"J Blum","year":"2001","unstructured":"Blum, J., Nkunku, S. & Burri, C. Clinical description of encephalopathic syndromes and risk factors for their occurrence and outcome during melarsoprol treatment of human African trypanosomiasis. Trop. Med. Int. Health. 6(5), 390\u2013400 (2001).","journal-title":"Trop. Med. Int. Health."},{"key":"3295_CR23","doi-asserted-by":"publisher","first-page":"248914","DOI":"10.1155\/2011\/248914","volume":"2011","author":"JM Kagira","year":"2011","unstructured":"Kagira, J. M. et al. Prevalence and types of coinfections in sleeping sickness patients in Kenya (2000\/2009). J. Trop. Med. 2011, 248914 (2011).","journal-title":"J. Trop. Med."},{"issue":"2","key":"3295_CR24","doi-asserted-by":"publisher","first-page":"e0118370","DOI":"10.1371\/journal.pone.0118370","volume":"10","author":"CD Kato","year":"2015","unstructured":"Kato, C. D. et al. Clinical profiles, disease outcome and co-morbidities among T. b. rhodesiense sleeping sickness patients in Uganda. PLoS ONE 10(2), e0118370 (2015).","journal-title":"PLoS ONE"},{"issue":"3","key":"3295_CR25","doi-asserted-by":"publisher","first-page":"e968","DOI":"10.1371\/journal.pntd.0000968","volume":"5","author":"I Kuepfer","year":"2011","unstructured":"Kuepfer, I. et al. Clinical presentation of T.b. rhodesiense sleeping sickness in second stage patients from Tanzania and Uganda. PLoS Negl. Trop. Dis. 5(3), e968 (2011).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"3295_CR26","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s13223-019-0377-7","volume":"15","author":"J Nsubuga","year":"2019","unstructured":"Nsubuga, J., Kato, C. D., Nanteza, A., Matovu, E. & Alibu, V. P. Plasma cytokine profiles associated with rhodesiense sleeping sickness and falciparum malaria co-infection in North Eastern Uganda. Allergy Asthma Clin. Immunol. 15, 63 (2019).","journal-title":"Allergy Asthma Clin. Immunol."},{"key":"3295_CR27","first-page":"12","volume":"20","author":"NW Maina","year":"2010","unstructured":"Maina, N. W., Thuita, J. K., Oberle, M., Ndung\u2019u, J. M. & Brun, R. Co-infection of sleeping sickness patients with malaria and loiasis in southern Sudan. J. Protozool. Res. 20, 12\u201319 (2010).","journal-title":"J. Protozool. Res."},{"issue":"7646","key":"3295_CR28","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1136\/bmj.39485.592674.BE","volume":"336","author":"G Priotto","year":"2008","unstructured":"Priotto, G. et al. Safety and effectiveness of first line eflornithine for Trypanosoma brucei gambiense sleeping sickness in Sudan: Cohort study. BMJ 336(7646), 705\u2013708 (2008).","journal-title":"BMJ"},{"issue":"12","key":"3295_CR29","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1111\/j.1365-3156.2007.01948.x","volume":"12","author":"JA Blum","year":"2007","unstructured":"Blum, J. A. et al. Sleeping hearts: The role of the heart in sleeping sickness (human African trypanosomiasis). Trop. Med. Int. Health. 12(12), 1422\u20131432 (2007).","journal-title":"Trop. Med. Int. Health."},{"key":"3295_CR30","unstructured":"World Health Organization. Control and Surveillance of Human African Trypanosomiasis: Report of a WHO Expert Committee 2013."},{"issue":"2","key":"3295_CR31","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/0035-9203(91)90032-T","volume":"85","author":"J Pepin","year":"1991","unstructured":"Pepin, J. & Milord, F. African trypanosomiasis and drug-induced encephalopathy: Risk factors and pathogenesis. Trans. R. Soc. Trop. Med. Hyg. 85(2), 222\u2013224 (1991).","journal-title":"Trans. R. Soc. Trop. Med. Hyg."},{"key":"3295_CR32","doi-asserted-by":"crossref","unstructured":"Van Nieuwenhove S. Present Strategies in the Treatment of Human African Trypanosomiasis. (Dumas, M., Bouteille, B., Buguet, A. eds.) (Springer, 1999).","DOI":"10.1007\/978-2-8178-0857-4_15"},{"issue":"Suppl","key":"3295_CR33","doi-asserted-by":"publisher","first-page":"S65","DOI":"10.1017\/S0031182000017339","volume":"122","author":"P Ambroise-Thomas","year":"2001","unstructured":"Ambroise-Thomas, P. Parasitic diseases and immunodeficiencies. Parasitology 122(Suppl), S65-71 (2001).","journal-title":"Parasitology"},{"issue":"9709","key":"3295_CR34","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/S0140-6736(09)60829-1","volume":"375","author":"R Brun","year":"2010","unstructured":"Brun, R., Blum, J., Chappuis, F. & Burri, C. Human African trypanosomiasis. Lancet 375(9709), 148\u2013159 (2010).","journal-title":"Lancet"},{"issue":"12","key":"3295_CR35","doi-asserted-by":"publisher","first-page":"7040","DOI":"10.1128\/IAI.72.12.7040-7044.2004","volume":"72","author":"L MacLean","year":"2004","unstructured":"MacLean, L. et al. Severity of human african trypanosomiasis in East Africa is associated with geographic location, parasite genotype, and host inflammatory cytokine response profile. Infect. Immun. 72(12), 7040\u20137044 (2004).","journal-title":"Infect. Immun."},{"issue":"3","key":"3295_CR36","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1083\/jcb.137.3.715","volume":"137","author":"S Magez","year":"1997","unstructured":"Magez, S. et al. Specific uptake of tumor necrosis factor-alpha is involved in growth control of Trypanosoma brucei. J. Cell Biol. 137(3), 715\u2013727 (1997).","journal-title":"J. Cell Biol."},{"issue":"11","key":"3295_CR37","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.1086\/522011","volume":"196","author":"L Maclean","year":"2007","unstructured":"Maclean, L. et al. Spatially and genetically distinct African Trypanosome virulence variants defined by host interferon-gamma response. J. Infect. Dis. 196(11), 1620\u20131628 (2007).","journal-title":"J. Infect. Dis."},{"issue":"12","key":"3295_CR38","doi-asserted-by":"publisher","first-page":"1794","DOI":"10.1086\/320731","volume":"183","author":"B Namangala","year":"2001","unstructured":"Namangala, B., Noel, W., De Baetselier, P., Brys, L. & Beschin, A. Relative contribution of interferon-gamma and interleukin-10 to resistance to murine African trypanosomosis. J. Infect. Dis. 183(12), 1794\u20131800 (2001).","journal-title":"J. Infect. Dis."},{"issue":"6","key":"3295_CR39","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/j.pt.2018.04.002","volume":"34","author":"AH Fairlamb","year":"2018","unstructured":"Fairlamb, A. H. & Horn, D. Melarsoprol resistance in African trypanosomiasis. Trends Parasitol. 34(6), 481\u2013492 (2018).","journal-title":"Trends Parasitol."},{"issue":"Suppl","key":"3295_CR40","doi-asserted-by":"publisher","first-page":"S23","DOI":"10.1017\/S003118200001698X","volume":"122","author":"FE Cox","year":"2001","unstructured":"Cox, F. E. Concomitant infections, parasites and immune responses. Parasitology 122(Suppl), S23-38 (2001).","journal-title":"Parasitology"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-03295-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-03295-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-03295-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T18:02:59Z","timestamp":1670090579000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-03295-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,10]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["3295"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-03295-8","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,10]]},"assertion":[{"value":"30 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 December 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 December 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"23777"}}